MedTrace Logo

Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump

NCT01430000 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2014-04-17

No results posted yet for this study

Summary

Patients who completed the conventional treatment against HCV and relapsed (the virus appeared again in their blood) have no effective therapy.

Conditions

  • Hepatitis C

Interventions

BIOLOGICAL

Subcutan implantation of autologus skin graft after ex-vivo treatment

Subcutan implantation of autologus skin graft after ex-vivo treatment

Sponsors & Collaborators

  • Medgenics Medical Israel Ltd.

    lead INDUSTRY

Principal Investigators

  • Eithan Galun, Professor · No affiliation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01430000 on ClinicalTrials.gov